by Riley Nolan | Nov 18, 2022 | Events, Featured
A big THANK YOU to everyone who participated in the EpiVax’s 2022 Immunogenicity & Tolerance Seminar in Willemspark, Amsterdam, organized with Corine Kruiswijk of Intravacc. We learned about the importance of tissue-resident T memory cells, new developments in...
by Riley Nolan | Oct 31, 2022 | Featured, News
EpiVax Joins Intravacc, CEPI on Project to Develop Universal Betacoronavirus Vaccine PROVIDENCE, RI, October 31, 2022 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) is pleased to announce participation in a new project with Intravacc, funded by CEPI (Coalition for...
by Riley Nolan | Oct 17, 2022 | Events, Featured
We had a blast at AAPS PharmSci 360 in Boston! Thank you to everyone that attended our talks and poster sessions, and stopped by our booth or cocktail reception at Legal Seafoods! Pictures below! Talks: Anne De Groot, M.D., EpiVax, Inc. Deimmunization and...
by Riley Nolan | Sep 22, 2022 | Featured, Thinking Out Loud -Blog
FDA Awards $2M in Funding to EpiVax Host Cell Protein Study Remember when the CHO genome sequence came out? Ok, so you don’t, but we do! We built an app for that (see our paper entitled “Of [Hamsters] and Men”) and so, we will now perform validating...
by Riley Nolan | Sep 12, 2022 | Featured, News
PROVIDENCE, RI, September 12, 2022 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) is pleased to announce the award of a two-year, $2 million grant from the FDA’s Office of Center for Drug Evaluation and Research (CDER) to validate a method for immunogenicity risk...
